Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GNCAQ Stock Alerts

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo
Compare

GNCAQ vs. SCPS, ADTX, ARDS, TRVN, and NAVB

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Scopus BioPharma (SCPS), Aditxt (ADTX), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Genocea Biosciences (NASDAQ:GNCAQ) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Scopus BioPharma had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Scopus BioPharma Neutral

Summary

Genocea Biosciences and Scopus BioPharma tied by winning 1 of the 2 factors compared between the two stocks.

How does Genocea Biosciences compare to Aditxt?

Genocea Biosciences (NASDAQ:GNCAQ) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Given Genocea Biosciences' higher possible upside, equities research analysts clearly believe Genocea Biosciences is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Aditxt had 8 more articles in the media than Genocea Biosciences. MarketBeat recorded 8 mentions for Aditxt and 0 mentions for Genocea Biosciences. Aditxt's average media sentiment score of 0.72 beat Genocea Biosciences' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company Overall Sentiment
Genocea Biosciences Neutral
Aditxt Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
AditxtN/AN/A-$41.71M-$100.79 thousandN/A

15.5% of Aditxt shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Summary

Genocea Biosciences beats Aditxt on 6 of the 11 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Genocea Biosciences Neutral

Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Genocea Biosciences N/A N/A N/A

Trevena has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Genocea Biosciences Neutral

Genocea Biosciences has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Trevena beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Genocea Biosciences has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Navidea Biopharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCAQ vs. The Competition

Export
MetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$349.04M$6.52B$12.05B
Dividend YieldN/AN/A2.67%5.66%
P/E Ratio0.00N/A24.0024.42
Price / SalesN/A170.73515.84118.72
Price / CashN/A22.4427.4837.92
Price / BookN/A4.7610.606.82
Net IncomeN/A-$141.03M$3.57B$337.56M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+33.3%$17KN/AN/A9
ADTX
Aditxt
1.0226 of 5 stars		$0.02
-36.0%		N/A-100.0%$15KN/AN/A60
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+100.0%$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/A-99.9%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel